No evidence of persistent parvovirus B19 viremia among Iranian patients with HIV after a 1-year follow-up.

Authors:
Arezoo Aghakhani
Arezoo Aghakhani
Pasteur Institute of Iran
Iran
Minoo Mohraz
Minoo Mohraz
Iranian Research Center for HIV/AIDS
Tehran | Iran
Kayhan Azadmanesh
Kayhan Azadmanesh
Pasteur Institute of Iran
Iran
Monireh Kazemimanesh
Monireh Kazemimanesh
Pasteur Institute of Iran
Tehran | Iran
Setareh Mamishi
Setareh Mamishi
Tehran University of Medical Sciences
Iran
Mohammad Banifazl
Mohammad Banifazl
Iranian Society for Support of Patients with Infectious Diseases
Iran
Dr Amitis Ramezani, PhD
Dr Amitis Ramezani, PhD
Pasteur Institute of Iran
Infectiouse disease specialist
Tehran | Iran

Arch Virol 2016 May 10;161(5):1183-7. Epub 2016 Feb 10.

Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, 13164, Iran.

Recent studies have demonstrated that, in common with other latent viruses, parvovirus B19 infection can be controlled by the host immune response but may persist in some places such as the bone marrow. Persistent B19 infection has been found in both immunocompetent and immunocompromised individuals, such as patients infected with human immunodeficiency virus (HIV). However, there is limited data regarding long-term B19 viremia in HIV patients. In this study, we investigated virological and hematological findings, and also the clinical outcome, of seven cases of HIV/B19 coinfection (confirmed by PCR) after one year. These cases were provided from a previous study on patients with HIV infection that found B19 DNA in 13 cases. Seven of these 13 patients were available after 1 year, and we retested them for B19 viremia and B19-specific antibodies. B19 IgG was tested by ELISA, and B19 DNA was assessed by nested PCR. Anemia was not observed in these cases. All subjects had cleared viremia, but B19 IgG seroconversion occurred in two cases. No significant changes in CD4 and hemoglobin occurred. The results of this study indicate that B19 infection in HIV patients is a subtle infection and that B19 viremia is not a long-term event.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00705-016-2782-2DOI Listing
May 2016
5 Reads
2.28 Impact Factor

Publication Analysis

Top Keywords

b19 viremia
16
b19 infection
12
b19
11
infection b19
8
b19 dna
8
parvovirus b19
8
patients hiv
8
b19 igg
8
hiv patients
8
patients
6
hiv
5
viremia
5
cases
5
infection
5
previous study
4
provided previous
4
hiv infection
4
study patients
4
cases patients
4
retested b19
4

Similar Publications

Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV.

J Med Virol 2015 Jul 13;87(7):1124-9. Epub 2015 Mar 13.

Department of Virology, Pasteur Institute of Iran, Tehran, Iran.

The human parvovirus B19 (B19) usually causes a subclinical infection in immunocompetent individuals. Whereas immunocompromised individuals such as patients infected with HIV are at risk of persistent anemia due to B19 infection. Only few studies have been carried out on distribution and molecular epidemiology of B19 in Iran. Read More

View Article
July 2015

Infection due to parvovirus B19 in patients infected with human immunodeficiency virus.

Clin Infect Dis 1995 Jan;20(1):170-3

Department of Medicine, Hospital of the University of Pennsylvania.

Parvovirus B19 has been described as a cause of chronic anemia in immunosuppressed patients, including those infected with human immunodeficiency virus (HIV). In this study serological assays and the polymerase chain reaction (PCR) were used to establish the prevalence of both prior and active infection due to parvovirus B19 among a general population of 105 HIV-infected individuals (cohort I) and among 22 HIV-infected patients with anemia (cohort II). Eight individuals in cohort I (7. Read More

View Article
January 1995

Parvovirus B19-related anemia in HIV-infected patients.

Authors:
P R Koduri

AIDS Patient Care STDS 2000 Jan;14(1):7-11

Division of Hematology, Cook County Hospital and Rush Medical College, Chicago, Illinois 60612, USA.

Persistent infection with parvovirus B19 (B19) is an important treatable cause of anemia in HIV-infected patients. B19 has a tropism for erythroid progenitors and causes pure red cell aplasia (PRCA). The failure to produce neutralizing antibodies to the virus following B19 infection in immunodeficient persons may result in persistent viremia and chronic PRCA (B19-PRCA). Read More

View Article
January 2000